CN109431973B - Preparation method of gel for preventing altitude stress - Google Patents
Preparation method of gel for preventing altitude stress Download PDFInfo
- Publication number
- CN109431973B CN109431973B CN201811505052.9A CN201811505052A CN109431973B CN 109431973 B CN109431973 B CN 109431973B CN 201811505052 A CN201811505052 A CN 201811505052A CN 109431973 B CN109431973 B CN 109431973B
- Authority
- CN
- China
- Prior art keywords
- phase
- weight
- parts
- solvent
- homogenizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of gel for preventing altitude stress, which comprises the following steps: respectively configuring a D phase, an E phase, an F phase, a G phase and an H phase; the phase F comprises 20-30 parts by weight of stephania sinica diels extract; the G phase comprises 0.2-1.0 part by weight of an anti-allergic agent; the stephania sinica diels extract comprises the following components: 20-45 mg/g cepharanthine; 18-27 mg/g of cycleanine; 30-65 mg/g of levo-tetrahydropalmatine; adding the phase A into a main pot for homogenizing for 5-10 minutes, adding the phase B for homogenizing for 3-5 minutes, stirring and heating to 85-88 ℃, after homogenizing for 5-10 minutes, keeping the temperature in vacuum for 15-25 minutes, and cooling; cooling to 58-62 deg.C, adding phase C, stirring, and cooling; adding the rest phases at 40-45 deg.C, stirring, adding H phase, and homogenizing. The gel prepared by the preparation method has the advantages that the raw materials are based on the stephania sinica diels extract, the altitude stress is prevented by adopting external transdermal absorption, the morbidity of the acute altitude stress can be effectively reduced, and the morbidity of the acute altitude stress is reduced.
Description
Technical Field
The invention relates to the field of preparation methods of anti-altitude sickness drugs, and particularly relates to a preparation method of a gel for preventing altitude stress.
Background
The medical plateau refers to the area with an altitude of more than 3000 m, i.e. the altitude at which people arrive will produce different altitude reactions. The plateau area of China is very wide, the plateau area with the height of more than 3000 meters is about one fourth of the total area of the plateau area, the plateau area is mainly distributed in Tibet, Xinjiang and Qinghai, the number of people from inland to plateau exceeds 1500 ten thousand times every year, and the plateau area with different degrees of plateau reactions accounts for 60-90 percent, so the economic development and the people health of the plateau area are restricted.
The altitude sickness, also called acute altitude sickness, is that the human body enters a plateau area with an altitude of more than 3000 meters from a plain area, and the disease is developed within hours to days, symptoms such as headache, dizziness, nausea, palpitation, chest distress, shortness of breath, hypodynamia, sleep disorder and the like appear, and serious patients can vomit, edema, somnolence, coma and even die. At present, in the market and various researches, medicines or health-care foods aiming at altitude stress are mostly based on rhodiola rosea.
Disclosure of Invention
The invention provides a preparation method of a gel for preventing altitude stress, aiming at solving the technical problems.
The invention is realized by the following technical scheme:
a preparation method of a gel for preventing altitude stress comprises the following steps:
A. respectively preparing a D phase, an E phase, an F phase, a G phase and an H phase, uniformly dissolving the D phase, and mixing and uniformly dispersing the E phase; the phase D comprises the following raw materials: 1.0-3.0 parts by weight of solubilizer, 0.004-0.4 parts by weight of essential oil, 0.6-2.0 parts by weight of cooling agent and 5.0-15.0 parts by weight of solvent; the phase E comprises the following raw materials: 0.6-1.2 parts by weight of a preservative and 2.0-5.0 parts by weight of a solvent; the phase F comprises 20-30 parts by weight of stephania sinica diels extract; the phase G comprises 0.004-0.4 part by weight of essential oil; the phase H comprises 0.02-0.2 parts by weight of pigment, and the stephania sinica diels extract comprises the following components: 20-45 mg/g cepharanthine; 18-27 mg/g of cycleanine; 30-65 mg/g of levo-tetrahydropalmatine;
B. adding the phase A into a main pot for homogenizing for 5-10 minutes, adding the phase B for homogenizing for 3-5 minutes, stirring and heating to 85-88 ℃, after homogenizing for 5-10 minutes, keeping the temperature for 15-25 minutes in vacuum, and starting cooling; the phase A comprises the following raw materials: 30-65 parts of solvent, 5-10 parts of humectant, 0.03-0.1 part of chelating agent and 0.5-8 parts of thickening agent; 0.1-0.5 part by weight of a thickener for the phase B;
C. cooling to 58-62 deg.C, adding phase C, stirring, and cooling; the phase C comprises 0.5-0.8 part by weight of a pH regulator;
D. adding phase D, phase E, phase F and phase G at 40-45 deg.C, stirring, adding phase H, and homogenizing.
Compared with the prior art, the invention has the following advantages and beneficial effects:
1. the gel prepared by the preparation method has the advantages that the raw materials are based on the stephania sinica diels extract, the altitude stress is prevented by adopting external transdermal absorption, the morbidity of the acute altitude stress can be effectively reduced, and the morbidity of the acute altitude stress is reduced.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail below with reference to examples, and the exemplary embodiments and descriptions thereof are only used for explaining the present invention and are not used as limitations of the present invention.
Example 1
A preparation method of a gel for preventing altitude stress comprises the following steps:
A. respectively preparing a D phase, an E phase, an F phase, a G phase and an H phase, uniformly dissolving the D phase, and mixing and uniformly dispersing the E phase; the phase D comprises the following raw materials: 1.0-3.0 parts by weight of solubilizer, 0.004-0.4 parts by weight of essential oil, 0.6-2.0 parts by weight of cooling agent and 5.0-15.0 parts by weight of solvent; the phase E comprises the following raw materials: 0.6-1.2 parts by weight of a preservative and 2.0-5.0 parts by weight of a solvent; the phase F comprises 20-30 parts by weight of stephania sinica diels extract; the phase G comprises 0.004-0.4 part by weight of essential oil; the phase H comprises 0.02-0.2 parts by weight of pigment, and the stephania sinica diels extract comprises the following components: 20-45 mg/g cepharanthine; 18-27 mg/g of cycleanine; 30-65 mg/g of levo-tetrahydropalmatine;
B. adding the phase A into a main pot for homogenizing for 5-10 minutes, adding the phase B for homogenizing for 3-5 minutes, stirring and heating to 85-88 ℃, after homogenizing for 5-10 minutes, keeping the temperature for 15-25 minutes in vacuum, and cooling after no fine particles or obvious bubbles exist; the phase A comprises the following raw materials: 30-65 parts of solvent, 5-10 parts of humectant, 0.03-0.1 part of chelating agent and 0.5-8 parts of thickening agent; 0.1-0.5 part by weight of a thickener for the phase B;
C. cooling to 58-62 deg.C, adding phase C, stirring, and cooling; the phase C comprises 0.5-0.8 part by weight of a pH regulator;
D. adding phase D, phase E, phase F and phase G at 40-45 deg.C, stirring, adding phase H, and homogenizing.
The gel and the specific raw materials for each phase of this example can be used in the following Table 1.
TABLE 1
The essential oil can be added for refreshing and tranquilizing, and rhizoma Ligustici Chuanxiong and semen Myristicae can be added for transdermal absorption to accelerate rapid absorption of effective substances of herba Stephaniae Japonicae extract in gel for treating acute hyperemesis.
The composition is applied to the skin of temple, behind the ear, eyebrow, neck, and umbilical region for 2-4 hr before and after entering high altitude area. According to the clinical symptoms self-test questionnaire of altitude stress formulated according to the national military standard GJB 1098-91 of the people's republic of China and the diagnosis and treatment principles of acute altitude stress, the results of human body tests show that the gel provided by the invention can obviously reduce the graduation score of the symptoms of acute altitude stress and effectively reduce the incidence of acute altitude stress compared with a control group, thereby prompting that the gel has a good effect of preventing altitude stress.
Example 2
Based on the principle of the above embodiment, the present embodiment is basically the same as the above method steps, and only differs from the principle formula in specific content. In this example, the phases and their contents are given in table 2 below:
table 2:
the gel prepared according to the above ratio, the implementation and test data of the human body test are shown in the following table 2. The test subjects are 162 male Han nationality new soldiers, are healthy and 18-22 years old, all enter high-altitude areas for the first time, and are randomly and averagely divided into an experimental group and a control group. The experimental group uses the gel of the invention, and a proper amount of the gel is smeared on the skin of temples, behind ears, eyebrows, necks, umbilicals and the like 2 hours before entering a high-altitude area and after entering the high-altitude area, and then the gel is repeatedly used every 2 to 4 hours. The control group did not use any anti-hyperreflexia agent, and was not treated differently from the experimental group except that it was treated with gel.
The experimental group was continuously used 2 hours before entering high altitude area, i.e. altitude 3680 m, and 5 days after entering, and scored using "altitude response clinical symptoms self-test questionnaire" on days 1, 2, 3, 4, and 5, and the results are as follows in table 3:
table 3: AMS symptom score and incidence comparison between experimental and control groups (n = 81)
Acute altitude diseases are pathological reactions generated after a human body is exposed to a hypoxic environment for a short time. After entering the high-sea area, the number of people with acute altitude diseases is parabolic with the increase of days in the control group, and the number of people with high adverse reaction is the most on the 3 rd day. The number of people who have acute altitude sickness is also in a parabola form in the experimental group coated with the gel, but the incidence rate of acute altitude sickness can be effectively reduced, and particularly, the comparison effect is better after the number of days of use is increased.
The above-mentioned embodiments are intended to illustrate the objects, technical solutions and advantages of the present invention in further detail, and it should be understood that the above-mentioned embodiments are merely exemplary embodiments of the present invention, and are not intended to limit the scope of the present invention, and any modifications, equivalent substitutions, improvements and the like made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (4)
1. The preparation method of the gel for preventing the altitude stress is characterized by comprising the following steps of:
A. respectively preparing a D phase, an E phase, an F phase, a G phase and an H phase, uniformly dissolving the D phase, and mixing and uniformly dispersing the E phase; the phase D comprises the following raw materials: 1.0-3.0 parts by weight of solubilizer, 0.004-0.4 parts by weight of essential oil, 0.6-2.0 parts by weight of cooling agent and 5.0-15.0 parts by weight of solvent; the phase E comprises the following raw materials: 0.6-1.2 parts by weight of a preservative and 2.0-5.0 parts by weight of a solvent; the phase F comprises 20-30 parts by weight of stephania sinica diels extract; the G phase comprises 0.2-1.0 part by weight of an anti-allergic agent; the phase H comprises 0.02-0.2 parts by weight of pigment, and the stephania sinica diels extract comprises the following components: 20-45 mg/g cepharanthine; 18-27 mg/g of cycleanine; 30-65 mg/g of levo-tetrahydropalmatine;
B. adding the phase A into a main pot for homogenizing for 5-10 minutes, adding the phase B for homogenizing for 3-5 minutes, stirring and heating to 85-88 ℃, after homogenizing for 5-10 minutes, keeping the temperature for 15-25 minutes in vacuum, and starting cooling; the phase A comprises the following raw materials: 30-65 parts of solvent, 5-10 parts of humectant, 0.03-0.1 part of chelating agent and 0.5-8 parts of thickening agent;
0.1-0.5 part by weight of a thickener for the phase B;
C. cooling to 58-62 deg.C, adding phase C, stirring, and cooling; the phase C comprises 0.5-0.8 part by weight of a pH regulator;
D. adding phase D, phase E, phase F and phase G at 40-45 deg.C, stirring, adding phase H, and homogenizing.
2. The method as claimed in claim 1, wherein the stephania sinica diels extract includes the following components: cepharanthine 35.7 mg/g; the content of the cycleanine is 23.1 mg/g; l-tetrahydropalmatine 45.2 mg/g.
3. The method of claim 1, wherein the essential oil comprises eucalyptus oil 0.001-0.1 parts by weight, nutmeg 0.001-0.1 parts by weight, Chuanxiong rhizome 0.001-0.1 parts by weight, and sandalwood 0.001-0.1 parts by weight.
4. The method as claimed in claim 1, wherein the solvent, humectant, chelating agent and thickener in phase A are respectively water, sorbitol, EDTA-2NA and carbomer in weight parts of 36.58, 8, 0.07 and 0.8; the thickener of the phase B is xanthan gum, and the weight part of the xanthan gum is 0.3; the pH regulator of the phase C is triethanolamine, and the weight part of the pH regulator is 0.8; the solubilizer and the solvent in the phase D are respectively CO-40 and alcohol, the weight parts of the solubilizer and the solvent are respectively 3.0 and 12, the cool feeling agent in the phase D comprises 1 weight part of menthol and 0.3 weight part of borneol, and the essential oil in the phase D comprises 0.05 weight part of eucalyptus oil, 0.05 weight part of nutmeg, 0.05 weight part of ligusticum wallichii and 0.1 weight part of sandalwood; the preservative and the solvent in the phase E are caprylyl hydroxy-vorinic acid and propylene glycol respectively, and the weight parts of the preservative and the solvent are 0.8 and 5 respectively; the weight portion of the stephania sinica diels extract in the phase F is 30; the anti-allergic agent comprises phospholipid, a feverfew extract, a tea extract and magnolol, wherein the total weight part of the anti-allergic agent is 1, and the weight part of the pigment is 0.1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811505052.9A CN109431973B (en) | 2018-12-10 | 2018-12-10 | Preparation method of gel for preventing altitude stress |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811505052.9A CN109431973B (en) | 2018-12-10 | 2018-12-10 | Preparation method of gel for preventing altitude stress |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109431973A CN109431973A (en) | 2019-03-08 |
| CN109431973B true CN109431973B (en) | 2021-08-03 |
Family
ID=65557633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811505052.9A Active CN109431973B (en) | 2018-12-10 | 2018-12-10 | Preparation method of gel for preventing altitude stress |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109431973B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1738634A (en) * | 2002-11-15 | 2006-02-22 | 汪建平 | Extract of stephaniae sinica diels and methods of using the same |
| CN105147675A (en) * | 2014-04-14 | 2015-12-16 | 崔新明 | Method for preparing externally-used medicine gel for treating perianal ulcer |
| CN107510768A (en) * | 2016-06-15 | 2017-12-26 | 吴鹏飞 | A kind of draft bacteriostatic gel |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9186316B2 (en) * | 2012-12-11 | 2015-11-17 | Avon Products, Inc. | Stephanotis jasminoides extracts and methods of use |
| US10576077B2 (en) * | 2015-03-23 | 2020-03-03 | Southwest Research Institute | Pharmaceutical salt forms of Cepharanthine and Tetrandrine |
-
2018
- 2018-12-10 CN CN201811505052.9A patent/CN109431973B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1738634A (en) * | 2002-11-15 | 2006-02-22 | 汪建平 | Extract of stephaniae sinica diels and methods of using the same |
| CN105147675A (en) * | 2014-04-14 | 2015-12-16 | 崔新明 | Method for preparing externally-used medicine gel for treating perianal ulcer |
| CN107510768A (en) * | 2016-06-15 | 2017-12-26 | 吴鹏飞 | A kind of draft bacteriostatic gel |
Non-Patent Citations (4)
| Title |
|---|
| 中国産ハスノハカズラ属植物の化学成分と化学分類学の研究;閔知大等;《岐阜藥科大學紀要》;19860630;第35卷;第28-35页 * |
| 从华千金藤中提取颅痛定工艺的研究;梁柏林;《广西化工》;19960610;第25卷(第2期);第4-7页 * |
| 地不容生物碱成分研究;沈晓静等;《化学研究与应用》;20161231;第28卷(第12期);第1730-1734页 * |
| 金线吊乌龟茎叶中生物碱的研究(II);何丽等;《中药材》;20101031;第33卷(第10期);第1568-1570页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109431973A (en) | 2019-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brown et al. | Rhodiola rosea | |
| WO2022099527A1 (en) | Heart-nourishing and nerve-soothing pharmaceutical composition and method for preparation thereof and application thereof | |
| CN102293820B (en) | Application in the medicine of a kind of Chinese medicine composition patient's death incident after preparation reduces myocardial infarction | |
| CN109364076B (en) | Stephania japonica extract for preventing altitude stress and gel based on same | |
| CN109431973B (en) | Preparation method of gel for preventing altitude stress | |
| CN107582691A (en) | Compound phellodendron bark liquid paint is gargled gel | |
| CN106237268B (en) | It is a kind of to treat schizoid pharmaceutical composition and its application | |
| CN106726984A (en) | A kind of cosmetic composition and its application with whitening acne-removing | |
| CN112741887B (en) | Traditional Chinese medicine composition for treating depression | |
| CN109199984B (en) | Whitening and skin-care composition capable of changing powder into cream and preparation method thereof | |
| CN104257800B (en) | A kind of medicament of Acne treatment | |
| CN103181944A (en) | Application of cucurbitacins in preparing medicine used for treating acnes | |
| Modaresi et al. | The effects of aloe vera extract on reproductive parameters in mice | |
| CN108465061A (en) | It is a kind of to be used to treat pharmaceutical composition of Facial Recurrent Dermatitis and its preparation method and application | |
| CN103860947B (en) | A kind of medicament for the treatment of alopecia totalis and alopecia universalis | |
| Moid et al. | A review on medicinal properties of Blumea lacera | |
| CN105687037B (en) | A kind of Traditional Chinese medicine acne treatment mask and preparation method thereof | |
| CN117180331B (en) | External antipyretic traditional Chinese medicine composition, preparation method and application thereof and antipyretic gel plaster | |
| CN110251624B (en) | Preparation method of acne eliminating gel | |
| CN114767819B (en) | Pharmaceutical composition for treating narcolepsy and preparation method and application thereof | |
| CN111467405B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating psoriasis | |
| CN108404082B (en) | Compound traditional Chinese medicine preparation with effects of promoting blood circulation and relieving pain and preparation method thereof | |
| CN107375700A (en) | A kind of herbal composition preparation with prevention and treatment male infertility infertility | |
| CN109528864A (en) | A kind of drug and preparation method thereof for treating acne | |
| CN103705868A (en) | Pharmaceutical composition for treating hyperthyroidism and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |